VITOSS® Bone Graft Substitute Poster Presentation Scheduled for the 2008 CNS Annual Meeting

Business Wire, Sept 18, 2008

MALVERN, Pa. -- Orthovita, Inc. (NASDAQ:VITA), a spine and orthopedic biosurgery company, reported that Jeffrey McConnell, M.D., of the Pennsylvania Spine and Scoliosis Institute at OAA Orthopaedic Specialists in Allentown, will make a presentation related to Orthovita's VITOSS Bone Graft Substitute product at the 2008 Annual Meeting of the Congress of Neurological Surgeons (CNS), Section on Disorders of the Spine and Peripheral Nerves, being held in Orlando, Florida from September 20-25, 2008.

Dr. McConnell will give an oral poster presentation of an abstract entitled, "A comparison of -TCP BMA vs. RhBMP-2 in anterior lumbar interbody fusion: A prospective, randomized trial with 1-year interim clinical and radiographic outcomes." In addition to the one-year data included in the abstract, Dr. McConnell will present two-year data. Dr. McConnell's presentation is based on research conducted independently from Orthovita.

"This maturing data continues to show no difference in radiological and clinical outcomes," Dr. McConnell reported. "The results of this study will help surgeons make better informed bone graft selections for optimizing patient care in a cost-conscious environment."

Dr. McConnell's presentation is scheduled for September 22, 2008, from 4:00 p.m. to 5:45 p.m. in the Select Abstract Session.

About the Company

Orthovita is a spine and orthopedic biosurgery company with proprietary biomaterials and biologic technologies for the development and commercialization of synthetic, biologically active tissue engineering products. We develop and market synthetic-based biomaterials products for use in spine surgery, the repair of fractures and a broad range of clinical needs in the trauma, joint reconstruction, revision and extremities markets. Our near-term commercial business is based on our VITOSS([R]) Bone Graft Substitute technology platforms, which are designed to address the non-structural bone graft market by offering synthetic alternatives to the use of autograft or cadaver-based bone material, VITAGEL([R]) Surgical Hemostat, an adherent matrix and an impermeable barrier to blood flow, and VITASURE[TM] Absorbable Hemostat. Our longer-term U.S. clinical development program is focused on our internally developed CORTOSS([R]) Bone Augmentation Material technology platform, which is primarily designed for injections in osteoporotic spines to treat vertebral compression fractures.

Disclosure Notice

This press release may contain forward-looking statements regarding Orthovita's current expectations of future events that involve risks and uncertainties, including, without limitation, the development, regulatory approval, demand and market acceptance of our products; our ability to obtain FDA clearance for CORTOSS in the United States; and other aspects of our business. Such statements are based on management's current expectations and are subject to a number of substantial risks and uncertainties that could cause actual results or timeliness to differ materially from those addressed in the forward-looking statements. Other factors that may cause such a difference are listed from time to time in reports filed by the Company with the U.S. Securities and Exchange Commission (SEC), including but not limited to risks described in our most recently filed Form 10-K under the caption "Risks Factors." Further information about these and other relevant risks and uncertainties may be found in Orthovita's filings with the SEC, all of which are available from the SEC as well as other sources. Orthovita undertakes no obligation to publicly update any forward-looking statements.